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Approximately 6.3 million fractures occur each year in the U.S. [1] and 5 to 20% of these 
fractures result in nonunions [2]. A fracture results in nonunion when the bone fails to heal completely. 
Despite the high prevalence of fractures, there are no methods that currently exist to prevent nonunions.  
Presently, both surgical and nonsurgical treatments exist, however most nonunions require surgery[3].  
For patients who initially needed post fracture surgery, and resulted in a nonunion, a second surgery is not 
only painful but also very costly financially and time wise. Cell-based therapies would be especially 
advantageous for these patients since it’s less invasive and would aid also in bone regeneration.  
Cell-based therapies using rat adipose-derived stem cells (rASCs) provide one possible form of 
treatment for fractures.  rASCs are known to be multipotent [4], easily isolated, and , and can be 
induced to express an osteoblastic phenotype [5]. Recent reports indicate that ASCs are not as 
osteogenic as bone marrow stem cells, but their ready availability supports their use as a 
potential cell source [6]. One disadvantage of cell-based therapies is cells tend to disperse to other 
tissues, away from the initial delivery site [7]. It is important that a form of delivery is developed to allow 
the controlled release of cells, maintain the cell’s viability and their ability to differentiate along the 
osteoblast lineage. One solution is to use alginate, a well-known biocompatible hydrogel, which is 
derived from seaweed. This biopolymer is known to maintain the viability of cells after injection and 
could be used as a platform for stem cells as they are positioned in the body and.[8, 9]  However, alginate 
does not readily degrade in vivo for six months [10]. Before alginate can be used to deliver stem cells, a 
method of controlled degradation must be established to achieve controlled cell release. To date, there are 
no methods that control the degradation of alginate hydrogels in vivo. Several attempts have been made 
by using gamma irradiation, oxidization and a bifunctional crosslinker, however they have not been 
successful. [10, 11] 
The overall goal of this project is to develop a system of injectable hydrogels to deliver 
stem cells for the purposes of bone regeneration. First, a method was developed to incorporate 
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alginate lyase in alginate microbeads to achieve controlled degradation. Two methods were 
employed; combining alginate with PLGA particles loaded with alginate lyase and combining 
the alginate lyase directly with the alginate. The latter of the two methods resulted in controlled 
degradation of alginate microbeads. Using this method, controlled release parameters were 
established for both wound healing alginate and medical grade alginate. Consequently, we 
determined if the by-products of alginate lyase - mediated alginate degradation had an effect on 
the cell’s viability and osteogenic potential. This was determined through viability tests, real 
time PCR and biochemical assays. The development of this therapy could be used for any other 
tissue regeneration with stem cells once the controlled release parameters are optimized.  
Methods: The rASCs were isolated from the inguinal fat pads of male Sprague Dawley 
rats.  MG63s and GFP-rASCs were bought from Harlan Labs and the University of Missouri 
respectively. All cell types were microencapsulated at 25 x 10
6
 cells/ml alginate. 
 Equal volumes of alginate lyase solution and 4% UP LVM alginate were combined. 
Microbeads were formed using a micoencapsulator with an electrostatic potential of 6kV and a 
calcium crosslinking solution (75mM CaCl2, pH 7.4). The degradation of the microbeads was 
followed by the absorbance of the uronate products and the diameter of the microbeads over the 
period of twelve days every 48 hours. Once the cells were microencapsulated the degradation 
was followed by the number of cells released and in the case of GFP-rASCs, the fluorescence 
was also recorded. Additionally, the alkaline phosphatase specific activity and DNA content of 
these cells were measured. The viability of the released cells was analyzed by using live/dead 
staining and TUNEL assay. In addition, we ensured that the released cells maintained their 
osteogenic potential by demonstrating that they were able to produce osteogenic and angiogenic 
factors after treating the cells with osteogenic media for a week. We measured the mRNA levels 
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of the following genes; Osx, Runx2, Col1, Vegfa, Fgf2 and Bmp2, Noggin, Gremlin, Ocn. The 
following soluble factors were also measured; OCN, OPG, VEGF and FGF2. 
Results: Incorporating PLGA particles loaded with alginate lyase lead to no visible 
degradation of alginate microbeads. The controlled degradation of alginate microbeads was 
achieved by directly incorporating the alginate lyase with alginate.  The wound healing alginate 
required more alginate lyase compared to medical grade alginate to be degraded within the same 
period. Using the controlled release parameters for the medical grade alginate the controlled 
release of cells was obtained. The viability of the cells released ranged from 87% on day 2 to 
71% on day 12, and these cells were not in a process of apoptosis. The released cells produced 
factors associated with osteogenesis and angiogenesis.  
Discussion: PLGA particles loaded with alginate lyase were not able to achieve 
degradation which was partly due to the low encapsulation efficiency of the double emulsion 
method. In addition, the enzyme released from the PLGA particles was not active as a result of 
the harsh environment inherent to the double emulsion method. Directly incorporating the 
alginate lyase with the alginate resulted in controlled degradation; however the amount of 
alginate lyase required for the wound healing alginate compared to the medical grade alginate is 
greater. This could be directly related to the composition of the two types of the alginate. The 
wound healing alginate is free of impurities such as the polyphenols and endotoxins. In the 
presence of polyphenols, the activity of the alginate lyase is reduced. The exact mechanism by 
which endotoxins affect alginate lyase mediated alginate degradation remains unknown. Using 
the degradation parameters for medical grade alginate, the controlled release of cells was also 
achieved. The higher ratios of alginate lyase to alginate lead to faster cell release. The viability of 
the cells with the highest concentration of alginate lyase was 87% on day 2 and with the lowest 
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concentration 71% on day 12 indicating that the cells remained viable. The mRNA levels of 
Runx2, Osx, and Col1 were similar to the control while Bmp2, Grem1, Nog, Vegfa, Fgf were 
significantly higher than the control, indicating that genes involved in osteogenesis and 
angiogenesis were expressed. The levels of OCN, OPG, VEGF, and FGF2 produced, also 
demonstrated that the phenotype of these released cells was maintained. In fact, the released cells 
produced a significantly higher level of osteocalcin compared to the control, which is a late 







The Use of Hydrogels in Stem Cell Delivery 
 
Hydrogels have a gained special focus because of their ability to maintain a temporary 
support for cells as they facilitate the bidirectional transport of nutrients, gases and metabolic 
wastes. Furthermore, hydrogels are tunable to allow the incorporation of specific biochemical 
cues. In typical cell-based therapies, stem cells are used either solely by themselves or in 
conjunction with a biomaterial which acts as a scaffold at the site of interest. In order for the 
tissue regeneration to be complete, it is important that the cells implanted are released from the 
scaffold to aid in tissue regeneration. 
 The controlled release of cells is critical to the success of cell-based therapies. In this 
project, controlled release of cells will be achieved through the controlled degradation of alginate 
microbeads encapsulating cells. Microencapsulation is a technique which entraps cells in a semi-
permeable membrane, thereby immobilizing the cells. This semi-permeable membrane allows 
the inflow of molecules essential for cell survival and the out flow of metabolic products [12].  
 
Alginate and Alginate Degradation 
Alginate, a natural polymer is a polysaccharide which consists of (1-4)-linked-β-D 
mannuronic acid (M units) and α-L-guluronic acid (G units) monomers. It is a block copolymer 
where each block may be repeating units of mannuronic acid (poly (M)) or guluronic acid 
(poly(G)) or a random organization of mannuronic and guluronic units (poly(MG)) [13].  
Alginate can be found in the cell wall of brown algae and can also be synthesized by bacteria. 
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The advantage of alginate compared to synthetic polymers is its biocompatibility, availability in 
nature, economical value, forms hydrogel under relatively mild pH and temperature, and its 
ability to be sterilized [13]. Alginate is used to form a hydrogel by cross-linking it with divalent 
cations such as calcium or barium. The crosslinking occurs between the guluronic acids of 
neighboring chains. 
When ASCs are encapsulated using an electrostatic potential in a calcium crosslinking 
solution containing glucose as an osmolyte, the resulting microbeads contain a tunable number of 
cells in a bead diameter of 200µm [14]. These microbeads were used successfully as a delivery 
vehicle for subcutaneous injection of ASCs in mice and the cells remained viable for two months 
[8, 9]. Mass transfer issues are obviated due their small size and high surface to volume ratio. 
These studies have also shown that encapsulated ASCs can be induced to express a chondrocytic 
phenotype and to produce chondrogenic factors, suggesting that similar approaches will be 
successful for bone regeneration [15, 16]. 
Despite the many advantages of alginate, a central challenge remains – alginate does not 
degrade enzymatically within the human body and non-enzymic breakdown occurs very slowly. 
In vitro, release of cells is achieved by chelating Ca
++
 thereby breaking the crosslinks between 
chains. There have been attempts to control the rate of degradation of alginate constructs in vivo 
by decreasing the molecular weight through oxidation and γ-irradiation, thus inducing 
hydrolytically labile groups [10].  After six months, these constructs maintained their structure 
but elastic modulus was decreased and cell migration was increased. Another approach, involved 
the encapsulation of PLGA particles loaded with alginate-lyase [17], an enzyme that cleaves the 
β-1,4-glycosidic linkage between the monosaccharide units of the alginate through a β-
elimination reaction [18]. Finally another strategy used covalent crosslinking with bifunctional 
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groups to degrade alginate constructs [19]. These efforts have been partially successful in larger 
alginate constructs (4mm), but there are no methods to control the degradation of smaller 
alginate microbeads (200µm – 500µm), which are important for injectable applications. 
 
Evaluating Alginate Degradation 
 Currently, there are no methods to quantify alginate degradation therefore we have used 
multiple methods to follow the degradation. Measuring the absorbance of uronate products or the 
byproducts from a ketal reduction is possible, but for the purposes of quantification, a standard 
curve cannot be constructed. No single method is sufficient in characterizing the degradation, but 
together they complement each other thus aiding in the understanding of the degradation process. 
First degradation is followed by recording the absorbance of the uronate products at 235 nm. 
However, after the first 4 days our results show not much uronate products are produced but the 
morphology of the microbeads continues to change. Hence, the other method involves observing 
the bead’s morphology. This method is coupled with measuring the diameter of the alginate 
microbeads over the duration of the experiment. Therefore for most of the studies the absorbance 




Figure 1: Schematic of interpreting alginate degradation - degradation and no degradation of 
alginate microbeads through the morphology of the microbeads and absorbance of uronate 
products. 
 
The third method employed to follow the alginate microbead degradation, is through the 
release of the microencapsulated cells. As the integrity of the beads is compromised through 
degradation, the cells are released and migrate out of the microbeads.  In the cell release studies, 
the number of cells released was counted at each time point to follow the degradation of the 
alginate microbeads. 
 
SPECIFIC AIMS AND EXPERIMENTAL DESIGN 
The overall objective of this thesis is to develop a system of injectable microbeads to 
deliver stem cells for the purposes of bone regeneration, thereby allowing the cells to remain at 
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the area of injury, to proliferate and secrete soluble factors that will facilitate tissue regeneration. 
The overall hypothesis states that controlled degradation of alginate microbeads can be used to 
control the release kinetics of viable cells. 
Specific Aim 1: To determine if alginate-lyase incorporated into alginate hydrogels can 
effectively catalyze alginate degradation in a time and dose – dependent manner. There are two 
main approaches in achieving the controlled degradation of alginate hydrogels (a) PLGA 
particles loaded with alginate-lyase which could then be encapsulated in the alginate microbeads 
and (b) mixing alginate-lyase directly with alginate at temperature outside the enzyme’s active 
temperature range. The enzyme alginate-lyase is known to cleave the glycosidic bonds in the 
alginate through a β-elimination reaction [10]. The objectives of this specific aim were to (i) 
develop and optimize a method of incorporating alginate-lyase in alginate microbeads and (ii) 
establish controlled release parameters using wound healing alginate and medical grade alginate. 
Alginate microbeads will be made by using a microencapsulator and a calcium crosslinking 
solution. The degradation of the beads will be followed by the absorbance of uronate products, 
the diameter of the beads, and the number of cells released for the cell release studies. The 
working hypothesis is incorporating alginate-lyase into alginate microbeads can control the 
degradation kinetics of alginate microbeads. 
Specific Aim 2: To determine if alginate lyase - mediated alginate degradation has an 
effect on cell viability and osteogenic potential. Once the stem cells are released from alginate 
microbeads they must remain viable and multipotent to play an active role in bone regeneration. 
The objectives of this specific aim were to use Live/Dead staining, and the TUNEL assay to 
determine viability of the cells released from alginate microbeads and secondly, to use real time 
PCR and ELISAs to determine if the osteogenic potential of the released cells is maintained. The 
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mRNA levels of Col1, Runx2, Osx, Ocn, Noggin, Gremlin, Bmp2, Vegfa, Fgf2 will be measured 
and the protein levels of BMP2, VEGF, FGF2, and OPG using ELISAs, and osteocalcin using a 
radioimmunoassay. The working hypothesis was that the viability and phenotype of cells will 




Alginate Degradation Studies 
To test our hypothesis that time controlled degradation can be achieved by the 
incorporation of alginate-lyase into alginate microbeads, various ratios of alginate-lyase (units 
[U] of enzyme activity) to alginate [g] were combined to form microbeads. Two types of 
alginates were used: “wound healing” grade alginate (55% to 60% mannuronate units) 
(Protonal® LF10/60LS, FMC BioPolymer, Sandvika, Norway) and medical grade alginate (50% 
mannuronate units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC BioPolymer). 
Low viscosity alginate was dissolved in 0.9% (w/v) saline (Ricca Chemical, Arlington, TX) at a 
concentration of 40 mg/ml. Microbeads were created using a Nisco Encapsulator VAR V1 LIN-
0043 (Nisco Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow rate, nozzle with an inner 
diameter of 0.175 mm, an electrostatic potential of 6 kV and a calcium crosslinking solution [19, 
20]. The crosslinking solution contained 75 mM CaCl2, 90 mM glucose with 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.4 (Sigma Aldrich) (HEPES-buffered). 
Alginate microbeads were allowed to crosslink for an additional 10 minutes, washed with 0.9% 
(w/v) saline (Ricca Chemical) to remove the excess Ca
++
, and suspended in saline supplemented 






PLGA Particle Formation 
1. Solid in Oil in Water Double Emulsion 
PLGA particles were formed using a previously published solid in oil in water double 
emulsion method. [14] PLGA particles contained 1:10 ratio of alginate-lyase to PLGA (w/w) and 
the control PLGA particles had no alginate-lyase incorporated. Briefly, PLGA (50:50) [Sigma 
Aldrich] was dissolved in dichloromethane (DCM) [Sigma Aldrich] to obtain a final 
concentration of 20% (w/v). In addition, 2% alginate-lyase [Sigma Aldrich], trehalose [Sigma 
Aldrich] and 2% magnesium hydroxide [Sigma Aldrich] were added to the dissolved PLGA to 
create the first emulsion. A sonicator was used to combine components for one minute. This 
emulsion was added drop wise to an 8% PVA (w/v) solution [Sigma Aldrich] with continuous 
stirring to form a second emulsion. This double emulsion was combined with 4% (w/v) PVA to 
ensure the protein of interest was in the PLGA particles. Following this step, the DCM was 
removed using a rotor evaporator; the particles were washed twice with deionized water, 
collected and lyophilized. 
2. Solid in Oil in Oil Double Emulsion 
Prior to the production of PLGA particles, an alginate-lyase and trehalose mixture was 
made (1:4 ratio of alginate-lyase to trehalose) and lyophilized. PLGA particles contained 1:10 
ratio of alginate-lyase to PLGA (w/w) and the control PLGA particles had no alginate-lyase 
incorporated. Briefly, PLGA (50:50) [Sigma Aldrich] was dissolved DCM to obtain a final 
concentration of 20% (w/v). In addition, the lyophilized mixture of alginate-lyase and trehalose 
to produce a final concentration of 2% (w/v)) and 2% magnesium hydroxide [Sigma Aldrich] 
were added to the dissolved PLGA to create the first emulsion. A sonicator was used to combine 
components for one minute.  Poly(dimethylsiloxane) (silicone oil) [DC 200, Sigma Aldrich] was 
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added to the mixture to create a homogenous emulsion. This emulsion was added to heptane and 
constantly mixed for two hours to allow for the hardening of the PLGA particles. The PLGA 
particles were collected through filtration, washed twice with heptane [Sigma Aldrich] and 
allowed to dry in a dessicator. This method proved to be very difficult because of the silicone 
oil’s viscosity. As a result, another sample of PLGA particles were made following the protocol 
above but using a 1:1 ratio of silicone oil to peanut oil (from Arachis hypogaea) [Fluka, Sigma 
Aldrich]. 
 
Protein Release Studies 
To confirm that the PLGA particles were loaded with alginate-lyase, a protein release 
study was conducted. This was done by suspending the various PLGA particles in saline, and at 
each time point the samples were centrifuged, supernatant collected, and the particles were re-
suspended in saline. The protein released was quantified by the Micro Protein Assay [Pierce 
Biotechnology, Rockford, IL] and normalized by the weight of PLGA particles used. It is also 
important that the protein released is active, therefore the ability for the enzyme to produce 
uronate products was measured. This was done by using an aliquot of the samples collected each 
day for the protein release study and combining it with 0.5% (w/v) alginate solution, which was 
allowed to stay overnight and the absorbance of the uronate products were measured at 235 nm. 
 
Micro Protein Assay  
The total protein content was measured using the Pierce Macro BCA Protein Assay 
Reagent kit (Pierce Biotechnology, Rockford, IL). Reagents A and B were mixed in a 50:1 ratio 
to make the working reagent. 25 µl of each sample was aliquoted to 96-well plates, and 200 μl of 
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the working reagent was added to the sample plates. They were incubated at 37 
0
C for 30 
minutes and read on a plate reader at 570 nm. 
 
Incorporation of PLGA particles loaded with alginate-lyase into alginate microbeads to 
achieve controlled degradation 
PLGA particles were incorporated into alginate microbeads by encapsulating PLGA 
particles in a 1:70 (1 mg PLGA particles: 70 mg alginate) ratio. Once the beads were made they 
were suspended in saline with physiological levels of calcium (1.8 mM CaCl2) at 37 
0
C.   
 
Adipose Derived Stem Cells 
ASCs were isolated from 100-125g male Sprague-Dawley rats (n = 6) [4, 5]. Briefly, the 
inguinal fat pad was removed and transferred to a container with Dulbecco’s modified Eagle 
medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 3% sterile-filtered L-
glutamine-penicillin-streptomycin (P/S). The tissue was washed three times with Hank’s 
balanced salt solution (HBSS) (Invitrogen) and then incubated in 0.25% trypsin–
ethylenediaminetetraacetic acid (EDTA) for 30 minutes on a rocker at 37°C. Following 
trypsinization, the supernatant was discarded. Adipose tissue was cut into small pieces and 
incubated in a digestive cocktail containing collagenase type I (365 units/mL) (Sigma Aldrich) 
and dispase (3 units/mL) (Gibco, Carlsbad, CA) for four hours. After incubation, the oily upper 
layer was removed and the digest was quenched with an equal amount of MSCGM. The cells 
were separated, plated in T-175 flasks at 5,000 cells/cm
2 
and cultured in MSCGM at 37
 
°C and 
5% CO2. For the next two days the monolayers were washed with Dulbecco’s phosphate 
buffered saline (DPBS) (Invitrogen) and fed with MSCGM every 24 hours. Thereafter media 
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were changed every 48 hours and cells were cultured to confluence. First passaged cells were 
used for studies. 
ASCs were also isolated from green fluorescent protein (GFP) positive rats and cultured 
up to passage 6 for the cell release studies. 
 
Cell Release Studies 
 To test our hypothesis that controlled release of cells can be achieved through the 
controlled degradation of alginate microbeads, cells were encapsulated in various ratios of 
alginate-lyase to UV-sterilized medical grade alginate. ASCs were released from the culture 
plate by trypsinization, and collected by centrifugation after rinsing the cell pellet with MSCGM, 
the cells were suspended in the alginate lyase-alginate mixture at a concentration of 25 x 10
6
 
cells/ml. Alginate microbeads were then formed as previously described. Microencapsulated 
ASCs and GFP-ASCs were suspended in 40µm cell strainers (BD Falcon, Franklin Lakes, NJ) 
and cultured in MSCGM in non-tissue culture treated 6-well plates to limit proliferation of 
released cells in the well. Media were changed every 48 hours and each cell strainer was washed 
twice with 0.9% (w/v) saline to ensure that all the cells released were collected.  
1. Cell Number 
The number of cells released was counted using a Z1 particle counter (Beckman Coulter, 
Brea, CA). For the groups where the alginate microbeads did not fully degrade by the end of the 
12 day period, 82.5 mM sodium citrate was used to release the remaining cells. All cells were 
collected, suspended in 0.05% Triton-X100 (Sigma Aldrich) and used to determine the DNA 
content [Quant-iT ™ Picogreen® ds DNA Reagent, Invitrogen, CA] and the alkaline 
phosphatase specific activity. The percent cell release was calculated as a function of the total 
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number cells in the 0 U/g group (control). The total number of cells microencapsulated in the 
control group was determined by the summation of all the cells released during the 12 days and 
all the cells released on the 12
th
 day using 82.5 mM sodium citrate. 
To determine if our observations were applicable to other cell types, microbeads were 
prepared containing human osteoblast-like MG63 cells (American Type Culture Collection, 
Rockville, MD). Microbeads were cultured in DMEM supplemented with 10% fetal bovine 
serum (FBS; Gibco, Carlsbad, CA) and 1% penicillin-streptomycin.  
2. Alkaline Phosphatase Specific Activity 
To measure alkaline phosphatase specific activity, released cells were suspended in 0.05 
% Triton-X100 and lysed by sonication. Enzyme activity was measured as the ability to convert 
p-nitrophenylphosphate to p-nitrophenol pH at 10.25. This was normalized by the total protein 
content (Pierce Macro BCA Protein Assay kit, Pierce Biotechnology, Rockford, IL) in the cell 
lysate. 
       3.  Cell Viability 
a.  LIVE/DEAD Assay 
Viability of cells within the microbeads and released cells was measured using a 
LIVE/DEAD Viability kit (Invitrogen). Samples (200µl) were collected at each time point (days 
0, 2, 4, 6, 8, 10, and 12) for microbeads without alginate-lyase and on the days where the greatest 
cell release occurred for the microbeads incorporating alginate-lyase. The 200µl aliquots were 
transferred to a chamber slide and incubated for 30 minutes at 37°C in 0.9% saline containing 
4μM ethidium homodimer-1 and 2μM calcein-AM.  Images were obtained using a Zeiss LSM 
700-405 confocal microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY). Three images 
12 
 
were obtained for each well and then red and green cells were counted using Image-Pro Plus 
software (Media Cybernetics) to determine the percent viability. 
b. TUNEL Assay 
 To determine if cell death was due to apoptosis, the integrity of the cell’s DNA was 
measured using the TiterTACS™ Apoptosis Detection Kit following the manufacturer’s protocol 
(Trevigen, Gaithersburg, MD). At each time point, 300,000 cells from each well were used for 
the assay.  
 
Osteogenic Potential of Released rASCs  
For these experiments ASCs that were not microencapsulated were compared to ASCs 
released from microbeads containing either 0 U/g or 0.13 U/g alginate-lyase. To investigate the 
osteogenic potential of the cells released, the cells were collected at day 8 from the 0 U/g and 
0.13 U/g groups and treated with OM for 7 days. In addition ASCs that were never 
microencapsulated were also treated with OM for 7 days. First passage ASCs and released ASCs 
were plated 5000 cells/cm
2
 and cultured in MSCGM. Confluent cultures were treated with 
osteogenic medium (OM, Lonza) for 7 days followed by MSCGM for 24 hours. 
1. Alkaline Phosphatase Specific Activity 
Alkaline phosphatase specific activity was measured as previously described in 2.3.2. 
      2 Soluble Factor Quantification 
Enzyme-linked immunosorbent assays (ELISA) were used to measure the levels of 
fibroblast growth factor-2 (FGF2), osteoprotegerin (OPG), and vascular endothelial growth 
factor (VEGF) (R&D Systems, Minneapolis, MN) in the conditioned medium. The levels of 
osteocalcin were measured with a radioimmunoassay kit (Human Osteocalcin RIA Kit, 
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Biomedical Technologies, Stoughton, MA). All ELISAs and the radioimmunoassay were 
normalized by the DNA content.  
      3. RNA Extraction and Real Time PCR 
RNA was extracted 8 hours after the last media change using TRIzol ® [Invitrogen] and 
quantified with the Nanodrop Spectrophotometer (Thermo Scientific, Waltham, MA). Samples 
were then converted into cDNA by the reverse transcription of 1 µg RNA with random primers 
(Applied Biosystems, Warrington, UK) and Multiscribe Reverse Transcriptase (Applied 
Biosystems). The cDNA was analyzed for mRNA levels by real-time PCR using the StepOne 
Plus PCR System (Applied Biosystems). mRNA levels for the following proteins were 
measured; BMP2 (Bmp2), type I collagen (Col1), FGF2 (Fgf2), Osterix (Osx), Runx2 (Runx2), 
osteocalcin (Ocn), and VEGF-A (Vegfa). In addition the mRNA levels for BMP antagonists, 
Noggin (Nog) and Gremlin 1 (Grem1) were measured. All primers (Table 1) were designed 
using the Beacon Designer 7.0 program and then synthesized by the Eurofins MWG Operon 
(Huntsville, AL). The mRNA levels were quantified relative to a standard curve of known 
concentration, and results were normalized to the transcript levels of the housekeeping gene, 40S 










Table 1: Primer sequences used for the analysis of mRNA levels 
 
Gene  Type Sequence 
Bmp2 R CTT CCG CTG TTT GTG TTT GG 
  F TGT GAG GAT TAG CAG GTC TTT G 
Col 1 R AGT GAT AGG TGA TGT TCT GG 
  F CGA GTA TGG AAG CGA AGG 
Fgf2 R global gene sequence unknown 
  F global gene sequence unknown 
Grem1 R ATC AGC GAC AGA CGG GGC ATC T 
  F AAG CAC ATC ACC GGC CAA CGG 
Nog R CAG CAG CGT CTC GTT CAG 
  F GCC AGC ACT ATC TAC ACA TCC 
Ocn R Quiagen QuantiTect Primer_013414 
  F Quiagen QuantiTect Primer_01084573 
Osx R GLOBAL GENE 
  F GLOBAL GENE 
Rps18 R TGT ATT GTC GTG GGT TCT GC 
  F TCG CTA TCA CTG CCA TTA AGG 
Runx2 R AGA GGC AGA AGT CAG AGG 
  F TCC CCA TCC ATC CAT TCC 
Vegfa R TCC AGG GCT TCA TCA TTG C 




The results of the qualitative and morphometric analyses were calculated as the 
means ± SEM of six independent cultures per variable. Statistically significant differences 
between groups were determined by one-way ANOVA followed by Bonferroni’s modification of 
Student’s t-test. P values ≤ 0.05 were considered significant. All experiments were repeated to 






Alginate-Lyase Incorporated into Alginate Microbeads can Effectively 




Hydrogels used to deliver stem cells must be degradable in vivo to allow for the release of 
cells thus facilitating tissue regeneration. Alginate does not readily degrade in vivo. It has been 
shown to be present six months after implantation [10]. In this thesis alginate degradation is 
achieved by using alginate-lyase which is an enzyme that catalyses the depolymerization of 
alginate. It cleaves the glycosidic bonds between the monosaccharide units of the alginate 
through a β-elimination reaction. This reaction is specific to the alginate-lyase; it may only 
cleave the glycosidic bond between the mannuronic acids or guluronic acids or mannuronic acid 
and guluronic acid. In this study the alginate-lyase cleaves the glycosidic bonds between the 
mannuronic acids. This enzyme is found in organisms of the marine ecosystem such as algae, 
mollusks and microorganisms, and both marine and soil bacteria [21]. By using this enzyme we 
are able to control the time for complete degradation of alginate microbeads. This enzyme was 
incorporated in two ways (i) PLGA particles loaded with alginate-lyase which could then be 
encapsulated in the alginate microbeads and (ii) the enzyme can be mixed directly with alginate. 
The first method included the use of solid in oil in water, double emulsion to create PLGA 
particles loaded with alginate-lyase which were then incorporated into alginate microbeads. Only 
the latter method resulted in controlled degradation of alginate microbeads. Cell release studies 





Figure 2: β-elimination reaction of alginate-lyase with alginate. The vertical arrows indicate the 
cleavage site between (a) MM blocks (b) GG blocks and (c) MG blocks. Taken from M. 




PLGA particles were made using four different formulations. The quantity and activity of 
the enzyme released from these particles were measured.  Group C had the highest protein 
released however only group A had the ability to produce uronate products (Fig.3A). In any case, 
these PLGA particles were too big to be microencapsulated. As a result, we went ahead and 
incorporated group D’s PLGA particles in the alginate microbeads but there was no degradation 
(Fig. 4A). This was further confirmed when the PLGA particles were suspended in the 




Figure 3: Characterization of PLGA particles formed (A) Cumulative protein release from 
PLGA particles loaded with alginate-lyase and (B) the ability of the enzyme released to produce 
uronate products. A- Solid in oil in oil method using silicone oil, B-Solid in oil in oil using a 
ratio of 1:1 peanut oil: silicone oil, C- Solid in oil in oil using a ratio of 1:1 peanut oil: silicone 






Figure 4: Degradation of alginate (wound healing) microbeads with PLGA particles (A) 
Degradation of alginate microbeads encapsulating PLGA particles and (B) Degradation of 
alginate microbeads with PLGA particles in the surrounding media 50:50 PLGA Empty 1:100 (1 
mg PLGA particles: 100 mg alginate), 50:50 PLGA Empty 1:70 (1 mg PLGA particles: 70 mg 
alginate), 50:50 PLGA Alginate-lyase 1:100 (1mg PLGA particles loaded with alginate-lyase: 
100 mg alginate), 50:50 PLGA alginate-lyase 1:70 (1 mg PLGA particles loaded with alginate-






Controlled degradation of alginate microbeads made from both wound healing (Figs. 5, 
6) and medical grade (Fig. 7) alginate was a function of alginate-lyase concentration. For both 
alginate types, as the ratio of alginate-lyase to alginate increased, the time required for total 
degradation of the alginate microbeads decreased (Figs. 6A and 7A). Complete degradation was 
not observed in microbeads produced using 0.7 U/g in either alginate formulation over the 12 
day time course. Degradation of the wound healing grade alginate occurred within 4 days (Fig. 
6B) whereas degradation of the medical grade alginate required 6 days (Fig. 7B).  
Microbead diameter changed overtime in an enzyme-dependent manner that was 
formulation specific. Newly generated microbeads had an average diameter of 400 µm when 
placed in the degradation solution (saline with 1.8mM Ca
2+
). Incorporation of 28 U/g alginate-
lyase caused wound healing grade bead diameters to decrease by >100µm within 2 days. In 
contrast microbeads containing 0.7 U/g did not decrease significantly until day 12. There were 
no changes in diameter in the absence of enzyme (Fig. 6C). Similarly, medical grade alginate 
beads did not change size in the absence of enzyme (Fig. 7C). However, diameters increased by 
100µm in the presence of alginate-lyase and this effect occurred more rapidly at higher enzyme 
concentrations. 
Degradation of the medical grade alginate microbeads with no cells in MSCGM (data not 
shown) occurred faster compared to the same microbeads suspended in saline supplemented with 
physiological levels of calcium (1.8 mM Ca
2+
) (Fig 8).  
 
Cell release kinetics varied as a function of alginate-lyase content (Fig. 9A). Medical 
grade alginate microbeads with the highest concentration of alginate-lyase (1.4 U/g) released the 
cells in the shortest period of time (2 days) (Fig. 9B). A similar result was seen in the percent 
19 
 
release where the highest percentage of cells (63%) was released on day 2 from the 1.4 U/g 
microbeads (Fig. 9C). DNA content of the released cells confirmed these observations (Fig. 9D). 
Released cells had measureable alkaline phosphatase specific activity (Fig. 9F). The highest 
levels of enzyme activity were seen in cells that were encapsulated in beads with alginate-lyase 
content varying from 0.09 to 0.24 U/g.  Similar cell release kinetics were observed using GFP-
ASCs (Figs. 10A and 10B), and confirmed by measuring fluorescence (Fig. 10C).  Release of 
MG63 cells exhibited comparable kinetics (Figs. 10D, 10E).  Unlike the ASCs, however, 
alkaline phosphatase specific activity of the released MG63 cells was low and did not vary with 






Figure 5: Degradation of alginate (wound healing) microbeads with different formulations of 
alginate-lyase (U): alginate (g) (a wide range). (A) Visualization of alginate microbead 
degradation under an inverted light microscope (mag. = 10x), (B) absorbance of uronate 
products, and (C) diameter of beads as they degrade over the 12 day period. Data were analyzed 






Figure 6: Degradation of alginate (wound healing) microbeads with different formulations of 
alginate-lyase (U): alginate (g) (a small range (A) Visualization of alginate microbead 
degradation under an inverted light microscope (mag. = 10x), (B) absorbance of uronate 
products, and (C) diameter of beads as they degrade over the 12 day period. Data were analyzed 












Figure 7: Degradation of alginate (medical grade) microbeads with different formulations of 
alginate-lyase (U): alginate (g). (A) Visualization of alginate microbead degradation under an 
inverted light microscope (mag. = 10x), (B) absorbance of uronate products, and (C) diameter of 
beads as they degrade over the 12 day period. Data were analyzed using one-way ANOVA 










Figure 8: Degradation of alginate (medical grade) microbeads with different formulations of 
alginate-lyase (U): alginate (g) in MSCGM. (A) Visualization of alginate microbead degradation 
under an inverted light microscope (mag. = 10x), (B) diameter of beads as they degrade over the 
12 day period. Data were analyzed using one-way ANOVA followed by Bonferroni’s 








Figure 9: The release of rASCs from alginate (medical grade) microbeads with different 
formulations of alginate-lyase (U): alginate (g) over the 12 day period. (A) Visualization of the 
released rASCs from alginate microbeads under an inverted light microscope (mag. = 10x), (B) 
the number of released rASCs, (C) percent cell release, (D) total DNA content, and (E) total 
alkaline phosphatase specific activity in the cell lysate. Data were analyzed using one-way 




Figure 10: The release of GFP-conjugated ASCs and MG63 osteoblast-like cells from alginate 
(medical grade) microbeads with different formulations of alginate-lyase (U): alginate (g) over 
12 days. Top row – GFP-rASCs: (A) the number of released cells, (B) total DNA content, and 
(C) fluorescence. Bottom row – MG63s: (D) the number of released cells, (E) total DNA content, 
and (F) alkaline phosphatase specific activity in the cell lysate. Data were analyzed using one-




The in vivo degradation of alginate microbeads is critical to cell based therapies using 
alginate as the carrier. Alginate-lyase was incorporated into alginate microbeads in two ways (i) 
encapsulating PLGA particles loaded with alginate-lyase in alginate microbeads and (ii) the 
enzyme can be mixed directly with alginate to form microbeads. However, the first approach did 
not result in degradation. Initially, these particles were made using the solid in oil in water 
method. This is a double emulsion method where the trehalose, magnesium dihydroxide, protein 
of interest is dispersed in a polymer solution then emulsified in an external aqueous phase after 
which the solvent is evaporated. [11] A trial was done with incorporating these PLGA particles 
within alginate microbeads which resulted in no degradation (Fig. 5A). We moved on to 
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conducting another experiment where two controls were added representing the ideal case that 
all the alginate-lyase was released from the PLGA particles. Even with the alginate-lyase in the 
media it showed that there was not sufficient enzyme to degrade the alginate beads (Fig. 5B). 
Moreover, this double emulsion method is known to have a low encapsulation efficiency and due 
to its harsh environment inherent to the PLGA preparation, the protein may have been denatured. 
As a result, we moved to the second approach which produced more favorable results. 
Here the alginate and alginate-lyase were combined at a low temperature and used to produce 
alginate beads. Controlled alginate degradation was achieved by incorporating alginate-lyase into 
alginate microbeads made from both types of alginate. The wound healing alginate was used to 
create a model of the alginate-lyase mediated degradation which could be applied to the more 
expensive medical grade alginate. However, the results showed that the wound healing alginate 
required more alginate-lyase to be degraded within the same time frame. Hydrogels used to 
deliver stem cells must be degradable in vivo to allow for the release of cells thus facilitating 
tissue regeneration. Our results demonstrate that this can be achieved by the incorporation of 
alginate-lyase during microbead production using an electrostatic potential. The effects of the 
alginate-lyase are concentration dependent.  As the amount of incorporated enzyme is increased, 
the rate of microbead degradation is increased.  This correlation between enzyme content and 
alginate degradation was found with two different alginate formulations used in medical 
applications but there were some differences.  Wound healing grade alginate degraded more 
quickly based on release of uronate products and a decrease in bead diameter.  In contrast, 
medical grade alginate degraded over a longer period of time and the diameter of the microbeads 
increased.  Despite both types of alginate having similar ratios of M units to G units, differences 
in their purity including alginate chain length may have played a role [19].  The presence of 
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polyphenols in the wound healing alginate does not appear to be responsible, however, since 
polyphenols have been shown to reduce the activity of alginate-lyase in aerobic degradation [22, 
23] and degradation of the wound healing alginate microbeads occurred more rapidly. 
Degradation of alginate microbeads via alginate-lyase occurs by two mechanisms; 
enzymatic cleavage and ion exchange. In the first few days, degradation is primarily due to 
enzymic cleavage of the glycosidic bonds between the M units. In our system, this was 
evidenced by the production of uronate products in the first four days of incubation. Once the 
glycosidic bonds are broken, the Ca
++
 ion crosslinks become more susceptible to ion exchange. 
The alginate structure disintegrates as a result of the out flux of Ca
++
 ions, which are replaced by 
monovalent ions resulting in decreased cross-linking density and, thus, a weakened hydrogel 
structure associated with an increase in pore size [24]. This two part mechanism likely 
contributed to the changes observed in microbead diameter over the 12 day period. The reduced 
crosslinking density coupled with the inward diffusion of other molecules resulted in the 
swelling observed in medical grade alginate microbeads. It is possible that a similar process 
takes place with microbeads produced using wound healing grade alginate, but it is more likely 
that the rapid cleavage of glycosidic bonds caused erosion of the surface of the microbead 
resulting in a decreased diameter.  
The controlled release of cells was illustrated with various cell types demonstrating the 
versatility of the delivery system. For all three cell types, 1.4 U/g alginate-lyase released most of 
the cells on day 2, while 0.09 U/g caused a gradual release of cells up to day 12. Alginate 
degradation in the absence of cells occurred more slowly than when cells were present.  
Mammalian cells do not possess alginate-lyase activity, ruling out the possibility that the cells 
contributed to microbead degradation via an active process.  The difference in degradation 
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kinetics reflects the reduced alginate content of the microbeads due to the physical presence of 
the cells.  In addition, the cells may begin to leave the microbeads before total degradation 
occurs as observed with 0.35 U/g group where the majority of the cells were released on day 4, 
but without cells the total degradation did not occur in 12 days. Also in the presence of the cells 









































Alginate Lyase - Mediated Alginate Degradation does not have an Effect on 




In order for tissue regeneration to be complete, it is important that the cells implanted are 
not only able to secrete local factors but are also able to be released from the alginate 
microbeads. In addition alginate-lyase and the byproducts of alginate lyase - mediated 
degradation should have no diverse effects on the released cells so that their ability to aid in 
regeneration of the tissue is not decreased. Therefore the viability and osteogenic potential of the 
cells released must be maintained to ensure that the bone regeneration is complete. In the present 
study, we focused on developing a system of injectable hydrogels to deliver stem cells for bone 
regeneration. This injectable, cell delivery system would allow the cells to remain at the area of 




Cells microencapsulated in alginate without any alginate-lyase had a viability of 79% on 
day 2 to 64% on day 12 (Fig. 11B). During the same time period, the viability of the cells 
released from the microbeads in all the groups ranged from 87% to 71% (Fig. 12B). There was 
no difference in DNA integrity amongst all groups (Fig. 12C). As the cells were released from 
the alginate microbeads in all groups, they maintained their ability to produce alkaline 
phosphatase.  The cells released from the 0.13 U/g group maintained their ability to differentiate 
along the osteoblast lineage by producing significantly higher levels of osteocalcin and similar 
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levels of OPG, VEGF and FGF to monolayer cells that were neither previously 
microencapsulated nor exposed to alginate-lyase (Fig. 13A - F). The mRNA levels of RUNX2, 
Osx, OCN, and Col1 were similar to the control groups while the mRNA levels of VEGFa, 
FGF2, BMP2, Noggin, and Gremlin 1 showed a significant increase (Fig. 14A - I).  
 
 
Figure 11: The viability of microencapsulated rASCs without alginate-lyase. (A) Live/dead 
staining of rASCs within the 0 U/g alginate (medical grade) microbeads (Scale bar = 50 µm) on 
days 2, 4, 6, 8, 10, and 12, where green represents live cells and red represents dead cells, and 
(B) the percent viable cells. Data were analyzed using one-way ANOVA followed by 





Figure 12: The viability of  rASCs released from alginate (medical grade) microbeads made 
with different formulations of alginate-lyase (U): alginate (g) (Scale bar = 50 µm) (A) Live/dead 
staining of released rASCs, where green represents live cells and red represents dead cells, (B) 
the percent viable cells, and (C) TUNEL assay of released  rASCs (the horizontal bar represents 
the positive control generated) at the respective times; 1.4 U/g on day 2, 0.35 U/g on day 4, 0.24 
U/g on days 4 and 6, 0.18 U/g on day 8, 0.13 U/g on day 10, and 0.09 U/g on days 10 and day 
12. Data were analyzed using one-way ANOVA followed by Bonferroni’s modification of 





Figure 13: The response of rASCs to osteogenic media, that were not encapsulated (monolayer 
cells) (M), microencapsulated (µE) and released from 0 U/g and 0.13 U/g alginate (medical 
grade) microbeads. (A) DNA content, (B)  alkaline phosphatase specific activity in the cell 
lysate, (C) osteocalcin (OCN) levels, (D) osteoprotegerin (OPG) levels, (E) vascular endothelial 
growth factor (VEGF) levels, and (F) fibroblast growth factor 2 (FGF2) levels. Data were 
analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 




Figure 14: The mRNA levels in rASCs treated with osteogenic media that were not encapsulated 
(monolayer cells) (M), microencapsulated (µE) and released from 0 U/g and 0.13 U/g alginate 
(medical grade) microbeads. (A) Runt-related transcription factor 2 (Runx2), (B)  Osterix (Osx), 
(C) collagen type 1 (Col1), (D) bone morphogenetic protein 2 (Bmp2), (E) gremlin 1, (F) noggin, 
(G) vascular endothelial growth factor -A (Vegfa), (H) fibroblast growth factor (Fgf), and 
osteocalcin (Ocn). Data were analyzed using one-way ANOVA followed by Bonferroni’s 
modification of Student’s t-test. * p< 0.05 vs. M. 
 
DISCUSSION 
The viability of cells post-injection is critical to the success of injectable cell-based 
therapies. Injection of stem cells is known to result in low viability ranging from 1% to 32% 
because of the harsh environment at the injury site and the mechanical disruption of the cell 
membrane by extensional flow during ejection from the needle [25]. Delivering cells in 
crosslinked alginate by injection has been shown to improve cell viability because of its 
protective effects during ejection via “plug flow”.  This plug flow occurs when the hydrogel near 
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the wall acts as a lubricant, protecting the rest of the hydrogel by allowing it to stay intact and 
move through the needle [25]. 
Once the cells are injected, the alginate can provide further protection while retaining 
them at the injury site.  Our results indicate that cells encapsulated in the microbead formulations 
tested in this study are viable in the microbead environment, indicating favorable mass transfer 
of nutrients.  The small increase in the number of viable cells noted in microbeads produced 
without enzyme may have been due to proliferation or to retention of secreted factors within the 
microbead [26] or to limited apoptosis.  Moreover, inclusion of alginate-lyase in the alginate did 
not have a negative impact on viability of ASC released from the microbeads.  Indeed, viability 
of cells released from microbeads containing alginate was greater than from microbeads without 
enzyme.  This suggests that the weakened structure of the alginate microbead due to cleavage of 
glycosidic bonds may have improved nutrient transfer.  
Importantly, ASCs released from the microbeads retained their ability to differentiate 
along an osteoblastic lineage, not only to the same extent as ASCs that were never exposed to 
microencapsulation, but for some markers, to a greater extent.  At the time of release, cellular 
alkaline phosphatase specific activity was comparable for all formulations of microbead.  
Released cells cultured in monolayer to confluence and then for 7 days in osteogenic medium 
had comparable alkaline phosphatase activity to ASCs that had never been previously 
microencapsulated, two fold greater than seen in ASCs immediately following release.  
Similarly, mRNA levels for the osteogenic transcription factors Runx2 and Osx were not 
different compared to the monolayer cells, nor were mRNA levels for Col1.  
Our results also suggest that microencapsulation may enhance the osteogenic potential of 
the ASCs with respect to their ability to produce paracrine factors that stimulate bone formation.  
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The released ASCs exhibited reduced DNA content and increased osteocalcin production 
compared to the never-encapsulated ASCs after 7 days in OM.  This was correlated with 
increased levels of Bmp2 mRNA, suggesting that BMP2 might act as an autocrine/paracrine 
regulator of the microencapsulated cells.  Interestingly, expression of Bmp2 was accompanied by 
expression of its inhibitors, Grem1 and Nog, but in a differential manner.  The significance of 
this is not known at this time, but other studies have shown that these proteins are regulated 
independently [27]. 
There was not complete convergence between mRNA levels at 8 hours post-treatment 
with osteogenic medium and protein levels at 24 hours for a number of factors, including 
osteocalcin, VEGF and FGF2, which may reflect normal cellular transcription and translational 
controls.  Interestingly, mRNA expression was more sensitive to differences in microbead 
formulation.  Cells encapsulated in alginate containing alginate-lyase had greater expression of 
Bmp2, Grem1 and Fgf2 and lower expression of Opg than cells that had been encapsulated in 
alginate without enzyme.  Similarly, for some mRNAs, having the experience of encapsulation 
caused greater expression than seen in ASCs that had not been encapsulated, even though the 
same starting population of ASCs was used for these experiments.  Previous research has shown 
that glucocorticoids can decrease production of angiogenic factors [28], suggesting that the 
dexamethasone present in osteogenic medium may have inhibited VEGF production by the cells.  
The fact that Vegf mRNA was not affected and that the ASCs produced both Fgf2 mRNA and 







In conclusion we have developed a degradable and injectable delivery system for stem 
cells. The controlled degradation was achieved through the incorporation of alginate-lyase into 
alginate microbeads. This system has shown that it can be used with other cell types. The cells 
released remained viable and maintained the ability to differentiate into osteoblasts. These 
microencapsulated cells can be directly injected to the site of injury. Therefore, in cases where 
surgery is usually required for fractures or nounions, this stem cell delivery method can be used, 
allowing controlled release of cells and the production of factors thus enhancing tissue 
regeneration. 
FUTURE WORK and CLINICAL IMPLICATIONS  
Creating smaller microbeads that are less than 200 µm in width and achieving the 
controlled release of viable cells is a series of studies that will be done. This would enhance the 
mass transfer properties of this injectable delivery system and possibly increase the viability of 
the released cells. Smaller alginate microbeads would also lead to the use of a smaller needle for 
delivery. Following this study, an in vivo study will be carried out to test the ability of the 
delivery system to aid in the regeneration of bone and determine which ratio of alginate-lyase to 
alginate is optimal for bone regeneration. For example, the microbeads could be implanted into a 
metaphyseal defect and after several weeks, asses the bone growth in the fracture through micro 
CT amongst other methods.  
The factors produced by the microencapsulated cells are critical to the bone regeneration 
process. Therefore the conditions that best lead to the production of these local factors should be 
explored. This may take the form of investigating the effects of the various components of 
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osteogenic media and identifying which combinations illicit the greatest production of 
osteogenic local factors. Another study will be done looking at the various osmolytes used in the 
crosslinking solution and identifying an optimal osmolyte that leads to the greatest production of 
these same local factors. 
As previously suggested, an in vivo study should be done to determine the ideal ratio of 
alginate-lyase to alginate that is ideal for bone regeneration. Alternatively, a more extensive 
study should be done to determine when most cells migrate to the fracture. Based on this 
information, one could determine which ratio is best for the regeneration of bone.  
Clinically, the findings from this study would add to the knowledge for personalized 
therapies for fractures. Here the patient’s ASCs could be isolated, microencapsulated and 
delivered to the fracture. On a broader scale the parameters identified in this study can be applied 
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